{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-112383","form_type":"8-K","ticker":"TARA","cik":"0001359931","company_name":"Protara Therapeutics, Inc.","filed_at":"2025-11-19T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.225029+00:00","generated_at":"2026-05-16T18:23:32.865114+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Protara TARA-002 STARBORN-1: 100% clinical success in evaluable patients","bullets":["8/8 evaluable patients (100%) achieved clinical success at eight-week assessment.","80% (8/10) of patients that completed treatment achieved clinical success.","5/6 macrocystic patients had complete response; mixed cystic patient also complete response.","No serious adverse events; common AEs were swelling and fatigue; one discontinuation due to Grade 2 fatigue.","Two LMs patients reached 32-week post-treatment and remain disease-free."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-112383","json":"https://secwatch.observer/filing/0001213900-25-112383.json","markdown":"https://secwatch.observer/filing/0001213900-25-112383.md","text":"https://secwatch.observer/filing/0001213900-25-112383.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1359931/000121390025112383/0001213900-25-112383-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1359931/000121390025112383/ea0266384-8k_protara.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T18:23:32.865114+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}